~ Buy the TAZVERIK (tazemetostat hydrobromide) Drug Profile, 2024 PDF Report in the Report Store ~

TAZVERIK Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Tazverik, and when can generic versions of Tazverik launch?

Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-two patents protecting this drug.

This drug has three hundred and seventy-two patent family members in thirty-nine countries.

The generic ingredient in TAZVERIK is tazemetostat hydrobromide. One supplier is listed for this compound. Additional details are available on the tazemetostat hydrobromide profile page.

DrugPatentWatch^® Generic Entry Outlook for Tazverik

Tazverik was eligible for patent challenges on January 23, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Try a Trial

Summary for TAZVERIK

International Patents:	372
US Patents:	22
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	90
Clinical Trials:	13
Patent Applications:	346
Drug Prices:	Drug price information for TAZVERIK
What excipients (inactive ingredients) are in TAZVERIK?	TAZVERIK excipients list
DailyMed Link:	TAZVERIK at DailyMed

Drug patent expirations by year for TAZVERIK

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAZVERIK

Generic Entry Date for TAZVERIK^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: ⤷ Try a Trial NDA: 211723 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAZVERIK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jacob Soumerai, MD	Phase 1/Phase 2
MEI Pharma, Inc.	Phase 1/Phase 2
Genentech, Inc.	Phase 1

See all TAZVERIK clinical trials

Pharmacology for TAZVERIK

Drug Class	Methyltransferase Inhibitor
Mechanism of Action	Methyltransferase Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Multidrug and Toxin Extrusion Transporter 2 K Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for TAZVERIK

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for TAZVERIK

TAZVERIK is protected by thirty-eight US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAZVERIK is ⤷ Try a Trial.

This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TAZVERIK

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2

Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Methods of treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

FDA Regulatory Exclusivity protecting TAZVERIK

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial

INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷ Try a Trial

INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
Exclusivity Expiration: ⤷ Try a Trial

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TAZVERIK

When does loss-of-exclusivity occur for TAZVERIK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 15350108
Estimated Expiration: ⤷ Try a Trial

Patent: 21204706
Estimated Expiration: ⤷ Try a Trial

Brazil

Patent: 2017010166
Estimated Expiration: ⤷ Try a Trial

Canada

Patent: 67664
Estimated Expiration: ⤷ Try a Trial

China

Patent: 7249591
Estimated Expiration: ⤷ Try a Trial

Patent: 6650500
Estimated Expiration: ⤷ Try a Trial

Denmark

Patent: 20916
Estimated Expiration: ⤷ Try a Trial

Eurasian Patent Organization

Patent: 1791095
Estimated Expiration: ⤷ Try a Trial

European Patent Office

Patent: 20916
Estimated Expiration: ⤷ Try a Trial

Patent: 72742
Estimated Expiration: ⤷ Try a Trial

Finland

Patent: 20916
Estimated Expiration: ⤷ Try a Trial

Hungary

Patent: 62159
Estimated Expiration: ⤷ Try a Trial

Israel

Patent: 2182
Estimated Expiration: ⤷ Try a Trial

Patent: 6080
Estimated Expiration: ⤷ Try a Trial

Patent: 4252
Estimated Expiration: ⤷ Try a Trial

Japan

Patent: 29684
Estimated Expiration: ⤷ Try a Trial

Patent: 17537899
Estimated Expiration: ⤷ Try a Trial

Patent: 21073241
Estimated Expiration: ⤷ Try a Trial

Patent: 23062189
Estimated Expiration: ⤷ Try a Trial

Lithuania

Patent: 20916
Estimated Expiration: ⤷ Try a Trial

Mexico

Patent: 17006089
Estimated Expiration: ⤷ Try a Trial

Patent: 21006734
Estimated Expiration: ⤷ Try a Trial

Poland

Patent: 20916
Estimated Expiration: ⤷ Try a Trial

Portugal

Patent: 20916
Estimated Expiration: ⤷ Try a Trial

Singapore

Patent: 201703806X
Estimated Expiration: ⤷ Try a Trial

Slovenia

Patent: 20916
Estimated Expiration: ⤷ Try a Trial

South Korea

Patent: 2338802
Estimated Expiration: ⤷ Try a Trial

Patent: 170103768
Estimated Expiration: ⤷ Try a Trial

Patent: 210156840
Estimated Expiration: ⤷ Try a Trial

Spain

Patent: 47819
Estimated Expiration: ⤷ Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAZVERIK around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Singapore	11201406468Y	SALT FORM OF A HUMAN HI STONE METHYLTRANSF ERASE EZH2 INHIBITOR	⤷ Try a Trial
Chile	2013002898	Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.	⤷ Try a Trial
Spain	2931316		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Indicators of Generic Entry

Summary for TAZVERIK

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TAZVERIK

Recent Clinical Trials for TAZVERIK

Pharmacology for TAZVERIK

Anatomical Therapeutic Chemical (ATC) Classes for TAZVERIK

Patents protecting TAZVERIK

FDA Regulatory Exclusivity protecting TAZVERIK

When does loss-of-exclusivity occur for TAZVERIK?

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAZVERIK